Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Michael J Fallon"'
Autor:
Emma E Williams, Danielle McQuinn, Lauren G. Banaszak, Cameron Ninos, Ryan J. Mattison, Zhubin Gahvari, Aric C. Hall, Michael J Fallon, Kalyan VG Nadiminti
Publikováno v:
Blood. 140:6099-6101
Autor:
Lauren G. Banaszak, Paloma Cabral, Kelcy Smith-Simmer, Ayesha Hassan, Matthew J Brunner, Michael J Fallon, Lauren Lovrien, Danielle Golner, Luke Zurbriggen, Ryan J. Mattison, Zhubin Gahvari, Aric C. Hall, Kalyan VG Nadiminti, Erica Reinig, Jane Churpek
Publikováno v:
Blood. 140:10828-10829
Publikováno v:
Journal of Oncology Pharmacy Practice. 26:1374-1381
Purpose The goal of this survey was to identify opportunities for health systems to increase implementation and adoption of oncology-focused pharmacogenomics services. Methods An online survey assessing respondent demographics, baseline knowledge and
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 27(7)
Introduction Acute promyelocytic leukemia (APL) is a potentially curable malignancy with 4-year overall survival rates >90%. Early complications from the disease or its treatment may result in a loss of oral access and require alternative administrat
Autor:
Keng Hee Peh, Daniel J Przybylski, Michael J Fallon, Jason J Bergsbaken, Paul R Hutson, Menggang Yu, Dustin A Deming, Mark E Burkard
Publikováno v:
Journal of Oncology Pharmacy Practice. :107815522210912
Purpose Molecular tumor boards provide precision treatment recommendations based on cancer genomic profile. However, practical barriers limit their benefits. We studied the clinical utility of the precision medicine molecular tumor board (PMMTB) and
Autor:
Alexandra M. Harrington, Karen Carlson, Sibgha Gull Chaudhary, Mark B. Juckett, Muhammad Umair Mushtaq, Aric C. Hall, Ryan J. Mattison, Sameem Abedin, Guru Subramanian Guru Murthy, Michael J Fallon, Laura C. Michaelis, Peiman Hematti, Lyndsey Runass, Ehab Atallah, Natalie S. Callander
Publikováno v:
Leukemialymphoma. 62(1)
We compared the outcomes of salvage chemotherapy in 146 patients with relapsed (57.5%) or refractory (42.5%) AML who received CLAG-M (51%), MEC (39%) or CLAG (10%). Minimal residual disease (MRD) was assessed by flow cytometry. Bivariate, Kaplan-Meie
Autor:
Jessica N. Heck, Michael J Fallon
Publikováno v:
Journal of Oncology Pharmacy Practice. 21:388-392
Stevens–Johnson syndrome/toxic epidermal necrolysis overlap is an acute hypersensitivity reaction that compromises the integrity of mucous membranes and cutaneous tissue. While the pathophysiology of this syndrome has not been fully elucidated, it
Autor:
Michael J Fallon, Natalie S. Callander, Michael P Reed, Mary S Mably, Rory Joseph Makielski, Glenn Liu, Daniel Mulkerin, Jason R Jared
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 23(7)
Uniformity of evidence-based chemotherapy prescribing using approved, standard, or “core” regimens provides systems-based safety. Noncore chemotherapy regimens are non-standard-of-care regimens requested by physicians on a patient-by-patient basi
Publikováno v:
Antimicrobial Agents and Chemotherapy. 56:4422-4427
Methicillin-resistant Staphylococcus aureus (MRSA) isolates that are susceptible to vancomycin but are tolerant to its killing effect may present a potential challenge for effective treatment. This study compared the microbiologic characteristics of
Autor:
Alexandra M. Harrington, Ehab Atallah, Mark B. Juckett, Michael J Fallon, Muhammad Umair Mushtaq, Sameem Abedin, Laura C. Michaelis, Ryan J. Mattison, Karen-Sue B. Carlson, Lyndsey Runass, Sibgha Gull Chaudhary, Guru Subramanian Guru Murthy, Aric C. Hall
Publikováno v:
Blood. 132:2708-2708
Background Induction therapy for acute myeloid leukemia (AML) with a cytarabine-anthracycline regimen (7+3) is well-established; however, there is no standard salvage therapy for patients with relapsed/refractory AML (RR-AML). There is a paucity of d